Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $116.44 USD
Change Today -4.16 / -3.45%
Volume 490.3K
RARE On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Eric W. Linsley CPA, MBA

Former Board Observer, Ultragenyx Pharmaceutical Inc.
AgeTotal Calculated CompensationThis person is connected to 159 board members in 6 different organizations across 16 different industries.

See Board Relationships
----

Background*

Mr. Eric W. Linsley, CPA, MBA has been the Chief Financial Officer at Envisia Therapeutics Inc. since June 18, 2015. Previously, he was a Managing Partner at Pappas Ventures, where he was directly responsible for investments that led to several very successful acquisitions and public offerings. Prior to joining Pappas Ventures in 2000, he served as the Chief Financial Officer and Vice President of TriPath Imaging Inc. Mr. Linsley played a key role in the three-way merger ...

Read Full Background

Corporate Headquarters*

60 Leveroni Court
Novato, California 94949

United States

Phone: 415-483-8800
Fax: 415-483-8810

Board Members Memberships*

Director
Director
Director
Chairman of The Board
2008-Present
Director, Chairman of Audit Committee and Member of Compensation, Nomination & Governance Committee

Education*

MS
New York University
MBA
University of Pennsylvania - The Wharton School
BA
Trinity College

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RARE:US $116.44 USD -4.16

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ULTRAGENYX PHARMACEUTICAL IN, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.